Next Article in Journal
Development of a Mucoadhesive and an in Situ Gelling Formulation Based on κ-Carrageenan for Application on Oral Mucosa and Esophagus Walls. II. Loading of a Bioactive Hydroalcoholic Extract
Next Article in Special Issue
Correlation between Fatty Acid Profile and Anti-Inflammatory Activity in Common Australian Seafood by-Products
Previous Article in Journal
Fatty Acid Profiles and Production in Marine Phytoplankton
Previous Article in Special Issue
Chemically-Induced Production of Anti-Inflammatory Molecules in Microalgae
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle

Protective Effects of Fucoxanthin on Ultraviolet B-Induced Corneal Denervation and Inflammatory Pain in a Rat Model

1
Department of Neurosurgery, Mackay Memorial Hospital, Taipei 10449, Taiwan
2
Department of Medicine, Mackay Medical College, New Taipei 25245, Taiwan
3
Internal Medicine, Taipei Hospital, Ministry of Health and Welfare, New Taipei 24213, Taiwan
4
Department of Business Administration, National Taipei University, New Taipei 24741, Taiwan
5
Department of Physiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11049, Taiwan
6
Department of Optometry, Mackay Junior College of Medicine, Nursing and Management, New Taipei 11260, Taiwan
7
School of Life Science, National Taiwan Normal University, Taipei 10610, Taiwan
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Mar. Drugs 2019, 17(3), 152; https://doi.org/10.3390/md17030152
Received: 15 February 2019 / Revised: 27 February 2019 / Accepted: 28 February 2019 / Published: 5 March 2019
(This article belongs to the Special Issue Marine Anti-inflammatory Agents)
  |  
PDF [2360 KB, uploaded 5 March 2019]
  |  

Abstract

Fucoxanthin is a carotenoid with many pharmaceutical properties that is found in brown seaweed. However, the effects of fucoxanthin on corneal innervation and intense eye pain have not been extensively examined. To clarify the protective roles and underlying mechanisms of fucoxanthin on ocular lesions, we investigated the beneficial effects and mechanisms by which fucoxanthin ameliorates ultraviolet B (UVB)-induced corneal denervation and trigeminal pain. Treatment with fucoxanthin enhanced the expression of nuclear factor erythroid 2-related factor 2 in the cornea. Inhibition of typical denervation and epithelial exfoliation in the cornea were observed in rats treated with fucoxanthin following UVB-induced nerve disorders. Moreover, the active phosphorylated form of p38 MAP kinase (pp38) and the number of glial fibrillary acidic protein (GFAP)-positive neural cells were significantly reduced. Decreased expression of neuron-selective transient receptor potential vanilloid type 1 (TRPV1) in the trigeminal ganglia neurons was also demonstrated in rats treated with fucoxanthin after UVB-induced keratitis. Symptoms of inflammatory pain, including difficulty in opening the eyes and eye wipe behaviour, were also reduced in fucoxanthin-treated groups. Pre-treatment with fucoxanthin may protect the eyes from denervation and inhibit trigeminal pain in UVB-induced photokeratitis models. View Full-Text
Keywords: fucoxanthin; ultraviolet B; denervation fucoxanthin; ultraviolet B; denervation
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Chen, S.-J.; Lee, C.-J.; Lin, T.-B.; Peng, H.-Y.; Liu, H.-J.; Chen, Y.-S.; Tseng, K.-W. Protective Effects of Fucoxanthin on Ultraviolet B-Induced Corneal Denervation and Inflammatory Pain in a Rat Model. Mar. Drugs 2019, 17, 152.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top